Side-by-side · Research reference

FOXO4-DRIvsKPV

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BAnimal-StrongAUTO-DRAFTED13/39 cited

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

01Mechanism of Action

Parameter

FOXO4-DRI

KPV

Primary target

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

Pathway

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

Downstream effect

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Feedback intact?

—

No melanocortin receptor binding

Origin

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

Antibody development

—

02Dosage Protocols

Parameter

FOXO4-DRI

KPV

Animal dose (mouse)

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

—

Frequency (animal)

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

—

Human equivalent (theoretical)

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

—

Evidence basis

Animal / mechanistic

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

Route

SQ (animal)

No human route established.

—

Duration

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

4–8 weeks per cycle

Clinical status

No human trials completed

—

Standard dose

—

200–500 mcg / day SQ or oralDalle-Pang 2024

Frequency

—

Daily or 2–3× per week

Lower / starter dose

—

100 mcg / day

Reconstitution

—

Bacteriostatic water (SQ form)

Timing

—

No specific time; often taken with / before meals (oral)

Half-life

—

Hours (estimated; rapid tissue uptake)

04Side Effects & Safety

Parameter

FOXO4-DRI

KPV

Pulmonary hypertension risk

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

—

Context-dependent toxicity

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

—

Off-target apoptosis

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

—

Immune perturbation

Senescent cells contribute to immune surveillance; clearance effects unknown

—

Human safety unknown

No clinical trials — toxicity profile in humans not established

—

Injection site reaction

—

Mild irritation

GI symptoms

—

Rare nausea (oral form)

Pigmentation

—

None (unlike full α-MSH)Dalle-Pang 2024

Long-term safety

—

Limited human data

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

KPV

·Pregnancy / breastfeeding

Relative Contraindications

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

KPV

·Active autoimmune disease (theoretical)

05Administration Protocol

Parameter

FOXO4-DRI

KPV

1. Pre-clinical route

Subcutaneous injection used in rodent models. No human administration protocol exists.

Add 1 mL bacteriostatic water to vial per labelling.

2. Reconstitution (animal)

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

3. Dosing schedule

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

Morning preferred; oral form taken with / before meals.

4. Clinical development status

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Safety monitoring (proposed)

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.

29–31G insulin syringe (SQ form).

06Stack Synergy

FOXO4-DRI

— no documented stacks

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018